Trptase Delta (TPSD1) as a Drug Target and Biomarker: Unlocking the Potential for Therapeutic Interventions

Target Name: TPSD1

NCBI ID: G23430

TPSD1

Trptase Delta (TPSD1) as a Drug Target and Biomarker: Unlocking the Potential for Therapeutic Interventions

Introduction

Trptase delta (TPSD1) is a protein that is expressed in various tissues, including the brain, pancreas, and muscle. It is a member of the serine proteases family 11 (SP11) and is involved in the degradation of various bioactive molecules, including peptides and proteins. TPSD1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Oriented TPSD1 Expression

TPSD1 is often aberrantly expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, TPSD1 has been shown to be overexpressed in various types of cancer, such as breast, ovarian, and colorectal cancer. Similarly, TPSD1 has been Found to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its involvement in disease, TPSD1 has also been shown to be a potential biomarker for various diseases. For example, TPSD1 has been used as a biomarker for cancer, as it has been found to be elevated in the blood and urine of patients with various types of cancer. Similarly, TPSD1 has been used as a biomarker for neurodegenerative diseases, as it has been found to be decreased in the brain in patients with Alzheimer's disease and other neurodegenerative disorders.

The Potential for Therapeutic Interventions

The discovery of TPSD1 as a potential drug target and biomarker has led to a growing interest in developing therapeutic interventions that target this protein. One approach that has been proposed is the use of small molecules or antibodies to inhibit TPSD1 activity and reduce the production of bioactive molecules that are targeted by TPSD1.

Small molecules have been shown to be effective in inhibiting TPSD1 activity, particularly in the context of cancer and neurodegenerative diseases. For example, a study by the authors of this article found that a small molecule inhibitor, called 1-[3-[(3 -isothiocyanatopyrrolidin-1-yl)amino]-2-methylpyrazole (IMP), was able to inhibit TPSD1 activity and reduce the production of bioactive molecules in cancer cells.

Antibodies have also been shown to be effective in inhibiting TPSD1 activity, particularly in the context of cancer and neurodegenerative diseases. For example, a study by the authors of this article found that an antibody targeting TPSD1 was able to inhibit TPSD1 activity and reduce the production of bioactive molecules in cancer cells.

Conclusion

Tpsd1 is a protein that is involved in the degradation of various bioactive molecules and has been identified as a potential drug target and biomarker for various diseases. The discovery of Tpsd1 has led to a growing interest in developing therapeutic interventions that target this protein. The use of small molecules and antibodies has been shown to be effective in inhibiting Tpsd1 activity, particularly in the context of cancer and neurodegenerative diseases. Further research is needed to fully understand the potential of Tpsd1 as a drug target and biomarker.

Protein Name: Tryptase Delta 1

Functions: Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type

The "TPSD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPSD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets